Fecal ESBL Escherichia coli carriage as a risk factor for bacteremia in patients with hematological malignancies

Supportive Care in Cancer

Volumn 24, Issue 1, 2016, Pages 253-259

  Cornejo Juárez, Patricia ^a   Suárez Cuenca, Juan Antonio ^b   Volkow Fernández, Patricia ^a   Silva Sánchez, Jesús ^c   Barrios Camacho, Humberto ^c   Nájera León, Esmeralda ^c   Velázquez Acosta, Consuelo ^a   Vilar Compte, Diana ^a  

^a INSTITUTO NACIONAL DE CANCEROLOGÍA   (Mexico)

^b CENTRO MÉDICO NACIONAL 20 DE NOVIEMBRE   (Mexico)

^c INSTITUTO NACIONAL DE SALUD PÚBLICA   (Mexico)

Author keywords

Bloodstream infection; Colonization; Escherichia coli; Extended spectrum lactamase; Mortality

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; CLARITHROMYCIN; CLINDAMYCIN; COTRIMOXAZOLE; DICLOXACILLIN; DOXYCYCLINE; ERTAPENEM; EXTENDED SPECTRUM BETA LACTAMASE; LEVOFLOXACIN; LINEZOLID; MEROPENEM; METRONIDAZOLE; PENICILLIN G SODIUM; PIPERACILLIN PLUS TAZOBACTAM; VANCOMYCIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; BACTEREMIA; BACTERIAL COLONIZATION; BACTERIAL OVERGROWTH; BACTERIAL STRAIN; BACTERIAL TRANSLOCATION; BLOOD CULTURE; BLOODSTREAM INFECTION; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DEATH; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTION; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ESCHERICHIA COLI; FECES CULTURE; FEMALE; HEALTH CARE COST; HODGKIN DISEASE; HOSPITALIZATION; HUMAN; INFECTION RELATED COST; INFECTION RISK; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; COMPLICATION; ESCHERICHIA COLI INFECTIONS; FECES; HEMATOLOGIC NEOPLASMS; MICROBIOLOGY; MORTALITY; RISK FACTOR;

ADULT; BACTEREMIA; COHORT STUDIES; ESCHERICHIA COLI INFECTIONS; FECES; FEMALE; HEMATOLOGIC NEOPLASMS; HUMANS; MALE; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 84949084903     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-015-2772-z     Document Type: Article

References (34)

1. Arnan M, Gudiol C, Calatayud L, Liñares J, Dominguez MA, Batlle M et al (2011) Risk factors for, and clinical relevance of, faecal extended-spectrum β-lactamase producing Escherichia coli (ESBL-EC) carriage in neutropenic patients with haematological malignancies. Eur J Clin Microbiol Dis 30:355–360. doi:10.1007/s10096-010-1093-x
2. Yu WL, Chuang YC, Walther-Rasmussen J (2006) Extended-spectrum beta-lactamases in Taiwan: epidemiology, detection, treatment and infection control. J Microbiol Immunol Infect 39:264–277
3. Ben-Ami R, Rodríguez-Baño J, Arslan H, Pitout JD, Quentin C, Calbo ES et al (2009) A multinational survey of risk factors for infection with extended-spectrum beta-lactamase-producing enterobacteriaceae in nonhospitalized patients. Clin Infect Dis 49:682–690. doi:10.1086/604713
4. Melzer M, Petersen I (2007) Mortality following bacteraemic infection caused by extended spectrum beta-lactamase (ESBL) producing Escherichia coli compared to non-ESBL producing E. coli. J Infection 55:254–259
5. Clinical and Laboratory Standards Institute (2011) Performance standards for antimicrobial susceptibility testing. 21st Informational Supplement, M-100-S21. Wayne, PA, USA: CLSI
6. Kaufmann ME (1988) Pulse-field gel electrophoresis. Methods Mol Med 15:17–31
7. Akpaka PE, Legall B, Padman J (2010) Molecular detection and epidemiology of extended-spectrum beta-lactamase genes prevalent in clinical isolates of Klebsiella pneumoniae and E. coli from Trinidad and Tobago. West Indian Med J 59:591–596
8. Tenover FC, Arbeit RD, Goering RV, Mickelsen PA, Murray BE, Persing DH, Swaminathan B (1995) Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol 33:2233–2239
9. Clermont O, Bonacorsi S, Bingen E (2000) Rapid and simple determination of the Escherichia coli phylogenetic group. Appl Environ Microbiol 66:4555–4558
10. Kieser T (1984) Factors affecting the isolation of CCC DNA from Streptomyces lividans and Escherichia coli. Plasmid 12:19–36
11. Espinal P, Garza-Ramos U, Reyna F, Rojas-Moreno T, Sanchez-Perez A, Carrillo B et al (2010) Identification of SHV-type and CTX-M-12 extended-spectrum beta-lactamases (ESBLs) in multiresistant Enterobacteriaceae from Colombian Caribbean hospitals. Chemotherapy 22:160–164
12. Prodinger WM, Fille M, Bauernfeind A, Stemplinger I, Amann S, Pfausler B et al (1996) Molecular epidemiology of Klebsiella pneumoniae producing SHV-5 beta-lactamase: parallel outbreaks due to multiple plasmid transfer. J Clin Microbiol 34:564–568
13. Berçot B, Poierel L, Silva-Sánchez J, Nordmann P (2010) Association of the extended-spectrum beta-lactamase gene blaTLA-1 with a novel ISCR element, ISCR20. Antimicrob Agents Chemother 54:4026–4028. doi:10.1128/AAC.00075-10
14. Chen CY, Tsay W, Tang JL, Tien HF, Chen YC, Chang SC, Hsueh PR (2009) Epidemiology of bloodstream infections in patients with haematological malignancies with and without neutropenia. Epidemiol Infect 27:1–8. doi:10.1017/S0950268809991208
15. Levin BR (2001) Minimizing potential resistance: a population dynamics view. Clin Infect Dis 33:S161–S169
16. Smith DL, Dushoff J, Perencevich EN, Harris AD, Levin SA (2004) Persistent colonization and the spread of antibiotic resistance in nosocomial pathogens: resistance is a regional problem. Proc Natl Acad Sci U S A 101:3709–3714
17. Tancrede CH, Andremont AO (1985) Bacterial translocation and Gram-negative bacteremia in patients with hematological malignancies. J Infect Dis 152:99–103
18. Yu WL, Chuang YCH, Rasmussen JW (2006) Extended-spectrum beta-lactamases in Taiwan: epidemiology, detection, treatment and infection control. J Microbiol Immunol Infect 39:264–277
19. Ellis M (2008) Febrile neutropenia. Evolving strategies. Ann N Y Acad Sci 1138:329–350
20. Ilan Y (2012) Leaky gut and the liver: a role for bacterial translocation in nonalcoholic steatohepatitis. World J Gastroenterol 18:2609–2618. doi:10.3748/wjg.v18.i21.2609
21. Van Leeuwen PAM, Boermeester MA, Houdijk APJ, Ferwerda CC, Cuesta MA, Meyer S, Wesdorp RIC (1994) Clinical significance of translocation. Gut Suppl 1:S28–S34
22. Hu B, Ye H, Xu Y, Ni Y, Hu Y, Yu Y et al (2010) Clinical and economic outcomes associated with community-acquired intra-abdominal infections caused by extended spectrum beta-lactamase (ESBL) producing bacteria in China. Curr Med Res Opin 26:1443–1449. doi:10.1185/03007991003769068
23. Cornejo-Juárez P, Pérez-Jiménez C, Silva-Sánchez J, Velázquez-Acosta C, González-Lara F, Reyna-Flores F et al (2012) Molecular analysis and risk factors for Escherichia coli producing extended-spectrum β-lactamase bloodstream infection in hematological malignancies. PLoS One 7(4):e35780
24. Hayakawa K, Gattu S, Marchaim D, Bhargava A, Palla M, Alshabani K et al (2013) Epidemiology and risk factors for isolation of Escherichia coli producing CTX-M-type extended-spectrum β-lactamase in a large U.S. medical center. Antimicrob Agents 57:4010–4018. doi:10.1128/AAC.02516-12
25. Liss BJ, Vehreschild JJ, Cornely OA, Hallek M, Fätkenheuer G, Wisplinghoff H et al (2012) Intestinal colonisation and blood stream infections due to vancomycin-resistant enterococci (VRE) and extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL) in patients with haematological and oncological malignancies. Infection 40:613–619. doi:10.1007/s15010-012-0269-y
26. Schwaber MJ, Carmeli Y (2008) Carbapenem-resistant Enterobacteriaceae: a potential threat. JAMA 300:2911–2913. doi:10.1001/jama.2008.896
27. Kang CL, Chung DR, Ko KS, Peck KR, Song JH, Korean Network for study of infectious diseases (2012) Risk factors for infection and treatment outcome of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae bacteremia in patients with hematologic malignancy. Ann Hematol 91:115–121. doi:10.1007/s00277-011-1247-7
28. Falagas ME, Karaeorgopoulos DE (2009) Extended-spectrum β-lactamase-producing organisms. J Hosp Infect 73:345–354
29. Wu UI, Wang JL, Chen WC, Chang SC, Chen YC (2011) Risk factors and outcomes of Escherichia coli bacteremia caused by strains that produce CTX-M or non-CTX-M extended-spectrum-beta-lactamases. Eur J Clin Microbiol Infect Dis 30:33–39
30. Clermont O, Lavollay M, Vimont S, Deschamps C, Forestier C, Branger C et al (2008) The CTX-M-15 producing Escherichia coli diffusing clone belongs to a highly virulent B2 phylogenetic subgroup. J Antimicrob Chemother 61:1024–1028. doi:10.1093/jac/dkn084
31. Reyna-Flores F, Barrios H, Garza-Ramos U, Sánchez-Pérez A, Rojas-Moreno T, Uribe-Salas FJ et al (2013) Molecular epidemiology of Escherichia coli O25b-ST131 isolates causing community-acquired UTIs in Mexico. Diagn Microbiol Infect Dis 76:396–398. doi:10.1016/j.diagmicrobio.2013.03.026
32. Morfín-Otero R, Mendoza-Olazarán S, Silva-Sánchez J, Rodríguez-Noriega E, Laca-Díaz J, Tinoco-Carrillo P et al (2013) Characterization of Enterobacteriaceae isolates obtained from a tertiary care hospital in Mexico, which produces extended-spectrum β-lactamase. Microb Drug Resist 19:378–383. doi:10.1089/mdr.2012.0263
33. Paterson DL, Bonomo RA (2005) Extended-spectrum β-lactamases: a clinical update. Clin Microbiol Rev 18:657–686
34. Clermont O, Dhanji H, Upton M, Gribeel T, Fox A, Boyd D et al (2009) Rapid detection of the O25b-ST131 clone of Escherichia coli encompassing the CTX-M-15-producing strains. J Antimicrob Chemother 64:274–277. doi:10.1093/jac/dkp194